Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 18:S0092-8674(25)00854-2.
doi: 10.1016/j.cell.2025.07.032. Online ahead of print.

Conversion of IscB and Cas9 into RNA-guided RNA editors

Affiliations

Conversion of IscB and Cas9 into RNA-guided RNA editors

Chengtao Xu et al. Cell. .

Abstract

RNA-guided RNA editing represents an attractive alternative to DNA editing. However, the prevailing tool, CRISPR-Cas13, has collateral RNA cleavage activity that causes undesirable cytotoxicity in human cells. Here, we report an ultracompact RNA-editing platform engineered from IscB, which has comparable or higher activity than Cas13 but without cytotoxicity concerns. We show that IscB, the evolutionary ancestor of Cas9, has an intrinsic affinity for complementary single-stranded (ss)DNA and RNA. This activity becomes dominant when its double-stranded DNA binding activity is switched off through the deletion of its target-adjacent motif domain. The resulting R-IscB is comparable to or better than Cas13, can efficiently alter splicing outcomes in human cells, and can further mediate trans-splicing to correct any mutation at the mRNA level. R-IscB also drives efficient A-to-I editing on mRNA when fused to adenosine deaminase acting on RNA 2 (ADAR2) and mediates cleavage-based mRNA knockdown upon HNH engineering. Finally, we show that the same approach converts some Cas9s to RNA-targeting tools.

Keywords: A-to-I; CRISPR; Cas13; Cas9; Cmr; Csm; IscB; RNase; trans-splicing.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Yale University and Cornell University have filed provisional patents on RNA-targeting-based genome editing applications by the engineered IscB and Cas9.

LinkOut - more resources